Ensign Peak Advisors
KZR

Ensign Peak Advisors’s Kezar Life Sciences KZR Stock Holding History

Ensign Peak Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,692
Closed -$612K – 1781
2022
Q4 		$612K Sell
8,692
-1,166
-12% -$86.5K ﹤0.01% 1543
2022
Q3 		$848K Buy
+9,858
New +$958K ﹤0.01% 1161

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Ensign Peak Advisors's KZR Position: Q1 2023 in Review

Ensign Peak Advisors sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 8,692 shares — an estimated $612K sold.

Ensign Peak Advisors first reported a position in KZR in Q3 2022 and held it in 2 quarters. The position peaked at $848K in Q3 2022. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Ensign Peak Advisors reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 8,692 Kezar Life Sciences shares in Q1 2023, an estimated $612K.
  • Ensign Peak Advisors first reported a position in Kezar Life Sciences in Q3 2022 and held it in 2 quarters.
  • Ensign Peak Advisors's Kezar Life Sciences position peaked at $848K in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Ensign Peak Advisors's 13F filing for Q1 2023, filed 15 May 2023.